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ABSTRACT 
Aims: The PREDICT Study is a prospective cohort study designed to evaluate coronary 
artery calcification score (CACS) as a predictor of cardiovascular events in Type 2 
diabetes (T2DM). 
Methods and Results: 589 patients with no history of cardiovascular disease and with 
established T2DM had CACS measured, as well as risk factors, including plasma 
lipoprotein, apolipoprotein, homocysteine and C-reactive protein concentrations, 
homeostasis model assessment insulin resistance (HOMA-IR) and urine albumin 
creatinine ratio. Participants were followed for a median of 4 years and first coronary 
heart disease (CHD) and stroke events were identified as primary endpoints. There were 
66 first cardiovascular events (including 10 strokes). CACS was a highly significant, 
independent predictor of events (p<0.001), with a doubling in CACS being associated 
with a 32% increase in risk of events (29% after adjustment). Hazard ratios relative to 
CACS in the range 0-10 Agatston units (AU) were: CACS 11-100AU, 5.4 (p=0.02); 101-
400AU 10.5 (p=0.001); 401-1000AU, 11.9 (p=0.001) and >1000AU, 19.8 (p<0.001). 
Only HOMA-IR predicted primary endpoints independently of CACS (p=0.01). The 
areas under the ROC curve for UKPDS risk engine primary endpoint risk and for UKPDS 
risk plus CACS were 0.63 and 0.73, respectively (p=0.03). . 
Conclusion: Measurement of CACS is a powerful predictor of cardiovascular events in 
asymptomatic patients with type 2 diabetes and can further enhance prediction provided 
by established risk models.  
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Cardiovascular disease (CVD), especially coronary heart disease (CHD), is the most 
common complication and the principal cause of death in Type 2 diabetes (T2DM). The 
risk of CHD is 2-5 times greater in patients with T2DM than in those free of the disease 1 
and there is evidence that its incidence can be reduced by control of hyperglycaemia, 
hypertension and dyslipidaemia 2. Methods are established for assignment of individual 
risk based on the major risk factors: age, gender, family history, smoking history, blood 
pressure, diabetes and lipid profile 3, 4. 
 
Diabetes is now considered a CHD equivalent and patients with T2DM are offered 
cardiovascular risk reduction. There may, nevertheless, be undetected subgroups at 
relatively low risk that should not be over-treated, while others may be at high risk and in 
need of more intensive risk modification. Furthermore, despite current treatments there is 
still an excess cardiovascular mortality in T2DM. 
 
Electron beam computed tomography (EBCT) enables high resolution, quantitative 
images of coronary artery calcification to be rapidly acquired. Coronary artery calcium is 
well-established as an index of atherosclerosis 5. Coronary artery calcium score (CACS) 
predicts CHD in non-diabetic groups 6 but there is uncertainty over whether it is equally 
effective in patients with diabetes and more information in this area is needed 7, 8. The 
primary aim of the Prospective Evaluation of Diabetic Ischaemic Disease by Computed 
Tomography (PREDICT) Study was to assess the role of the EBCT-derived coronary 
calcium score (CACS) in predicting CHD and stroke in patients with T2DM without 
existing clinical CVD. A secondary aim was to compare the ability of CACS and both 
conventional and novel risk factors and risk models to predict cardiovascular endpoints.
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METHODS 
The study was designed specifically to evaluate CACS as a predictor of first 
cardiovascular events in patients with T2DM free of clinical CVD and its protocol was 
published at the outset 9.  In summary, 589 patients with T2DM, recruited from outpatient 
diabetes clinics in Central and West London, U.K had coronary artery calcification 
measured. Recruitment started in November 2000, and finished in November 2003. Participants’ 
clinical status was reviewed annually up to November 2006. The median follow up time was 4 
years, as per our original protocol 9. Ethics committee approval for the study was obtained 
from each of the participating centres. All participants gave written, informed consent.  
 
Participants 
Participants had T2DM diagnosed by standard criteria and were on standard diabetic 
therapy, including diet, tablets or insulin. They were of either sex, aged 50 to 75 years 
and were Caucasian or Asian. Those of Black African origin were excluded because of 
their known low event rate for CHD in the U.K. at the time the study was planned 10. 
Other exclusion criteria were: known coronary artery disease or other cardiac disease; 
congestive heart failure; uncontrolled hypertension (baseline systolic BP >160 mmHg or 
diastolic BP >95 mmHg, with or without anti-hypertensive treatment);  pregnancy; 
inability to provide informed consent; or other medical conditions likely to limit life 
expectancy or requiring extensive medical treatment. 
 
Electron beam computed tomography 
As previously described 9, EBCT was carried out on an Imatron C-150 electron beam 
computed tomography scanner (Imatron Inc., San Francisco, CA, USA), which uses the 
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high resolution, single slice mode without contrast agent. The scan time was 100 ms with 
3 mm slices, electrocardiographic triggering and holding of breath by subjects. Total 
procedure time was 15 min with a radiation dose of 0.5– 0.9 mSv (cf U.K. annual 
background radiation of 2.5– 7.5mSv). Quantification of CACS was in Agatston units 
(AU)11. 
 
Biochemical measurements 
After an overnight fast, blood samples were taken for baseline measurement of plasma 
glucose, glycosylated haemoglobin (HbA1c),  specific insulin, total and HDL cholesterol, 
triglycerides,  apolipoproteins B (apoB) and AI (apoAI), LDL cholesterol (by Friedewald 
method), creatinine, fibrinogen,  homocysteine and high sensitivity CRP and urine 
creatinine albumin ratio, as previously described12, 13. Those patients being treated with 
insulin had taken no insulin since the previous day. 
 
Clinical endpoints 
Clinical endpoints were selected to be comparable with other recent cardiovascular trials 
in diabetes 14 and included: death due to MI or other cardiovascular causes, non-fatal MI, 
unstable angina, other objective evidence of coronary artery disease or stroke. Diagnoses 
of death from cardiovascular causes were obtained from the results of post-mortem 
examination. Non-fatal MI was determined from review of hospital case notes and 
required two or more of: typical symptoms, diagnostic ECG changes, or diagnostic 
enzyme changes. Unstable angina was diagnosed on the basis of clinical features of an 
acute coronary syndrome without diagnostic enzyme changes or need for hospital 
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admission or both. Other objective evidence of coronary artery disease included 
diagnostic thallium stress testing, coronary arteriogram showing >50% stenosis or a 
clearly positive exercise stress test. Stroke was defined as rapid onset of focal, global or 
neurological deficit, either lasting more than 24 hours or leading to death, with clinical 
findings supplemented by neurological imaging. Study size was originally estimated on the 
basis of an anticipated 2:3 ratio in the number of patients with CACS ≥100AU and CACS 
<100AU and a 1.5% annual event rate in those with CACS <100AU. A risk ratio of 2.5 between 
patients with CACS>100AU and with CACS<100AU would then be detected as significant 
(p<0.05) at 86% power with 600 patients, and an anticipated 57 events over 3 years of follow-up. 
9.  
 
Follow-up 
Clinical events were ascertained by direct contact with the patients and inspection of 
medical or other records. Relevant documentation of all reported events was reviewed by 
experienced clinicians not involved in the study to ensure that these fulfilled the protocol 
definitions.  Subjects received usual therapy throughout and, as set out in the original 
study protocol 9. Neither participants nor their physicians were informed of their CACS 
until their last follow-up visit, when they were given their scores on request. 
 
Data Analysis 
Insulin resistance was calculated from the fasting plasma glucose and insulin 
concentrations, according to the homeostasis model assessment (HOMA) formula 15. 
Presence of the Metabolic Syndrome was determined according to International Diabetes 
Federation (IDF) criteria 16. Ratios between apolipoprotein B and AI concentrations, and 
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between triglyceride and HDL cholesterol concentrations were calculated. In all analyses, 
CACS was evaluated in the 5 CACS categories: 0-10, 11-100, 101-400, 401-1000 and 
1001-10000 AU as widely used17, 18. Statistical analysis was carried out using STATA 9.2 
(StataCorp, Tx). Our analysis was designed to answer the following questions: 1) Is 
CACS a significant predictor of primary outcome events in the PREDICT cohort? 2) If 
CACS is a significant predictor, is this statistically independent of other, more readily 
measurable, risk factors? 3) If CACS is an independent predictor, can it improve risk 
prediction by the established Framingham and UKPDS risk models? To answer these 
questions, Cox proportional hazards modelling was used to predict time free of a first 
cardiovascular endpoint, with confirmation of the proportional hazards assumption for 
each model. The first question was addressed by entering CACS in the model as a 
continuous variable. CACS was also explored as a predictor in the categories 11-100, 
101-400, 401-1000, >1000 AU relative to the category 0-10. The second question was 
addressed in a multivariable model with CACS as a categorical predictor plus the 
classical risk factors: age, sex, South Asian ethnicity, cigarette smoking, duration of diabetes, 
cholesterol, HDL cholesterol, systolic BP, diastolic BP, antihypertensive use, lipid-lowering 
agent use. The following variables were also entered in the model, but only if they were 
significant (p<0.05) univariate predictors of primary outcomes: alcohol intake, exercise 
habit, BMI, waist circumference, waist hip ratio, heart rate, fasting plasma glucose, 
HbA1c, urine albumin/creatinine ratio, serum creatinine, total, LDL and HDL cholesterol, 
triglycerides, triglycerides/HDL cholesterol ratio, total cholesterol/HDL cholesterol ratio, 
apolipoproteins AI and B and the apoAI/apoB ratio, IDF metabolic syndrome, fasting 
plama insulin, HOMA-IR, fibrinogen, C-reactive protein and homocysteine . To answer 
the third question, the probability of a first CHD endpoint was estimated for each 
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PREDICT participant during their individual follow-up period using both the 
Framingham risk equations and the United Kingdom Prospective Diabetes Study 
(UKPDS) risk engine for CHD 3, 4 (version 3 of the UKPDS risk engine, kindly provided 
by Professor Rury Holman, was used in these analyses). CHD alone was considered since 
the Framingham equation for CVD includes peripheral vascular disease as an endpoint. 
The probability of a CVD primary endpoint was also estimated using the UKPDS risk 
engine (version 3 also provides risk estimates for CHD and stroke combined). To 
evaluate the ability of predictors to discriminate those who would experience an event, 
receiver operator characteristic (ROC) areas under the curve (AUC) were derived. 
Framingham and UKPDS CHD and UKPDS CVD risks were evaluated and, using 
predicted probabilities of a CHD or CVD event from Cox proportional hazards 
modelling, risks for each of these plus CACS as a continuous variable. The ROC AUCs 
for the Framingham or UKPDS risks alone were then compared with ROC AUC for the 
respective score plus CACS.  A conventional significance cut-off of p=0.05 was adopted 
throughout.
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RESULTS 
 
Study population 
Clinic records and interview identified 661 eligible patients of whom 39 declined 
participation in the study, 31 declined EBCT either because they did not wish to proceed 
in the study or were unable to attend for EBCT and 2 did not have CACS measured for 
technical reasons. The remaining 589 had CACS measured by EBCT. Their median 
(IQR) follow-up duration was 4.0 (3.0, 4.2) years, representing 2,256 person-years. Their 
clinical and biochemical characteristics on recruitment are given in Table 1 and their risk 
factor characteristics in successive categories of CACS in Table 2. Among the 33 recruits 
who did not proceed to EBCT, there were significantly fewer who were Caucasian, had 
metabolic syndrome or were being treated with antihypertensive drugs (Chi Square test, 
p<0.05). Un-scanned patients also tended to be younger (Mann Whitney U test, p=0.02). 
Results below relate exclusively to the 589 participants who underwent EBCT. 
 
Study endpoints 
During follow-up, 66 (11.2%) participants experienced a primary endpoint. The 
incidence rate overall was 31 per 103 person years. Figure 1 shows proportions of 
primary endpoints according to follow-up time. Non-fatal primary endpoints comprised 
36 coronary artery disease, 7 MI, 1 revascularisation, 5 unstable angina and 8 strokes. 
Fatal primary endpoints comprised 7 coronary events and 2 strokes. Overall, during the 
entire follow-up period, there were 19 non-cardiovascular deaths and 123 cardiovascular 
events recorded, including 13 cardiovascular deaths and 29 ‘hard’ endpoints comprising 
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non-fatal MI, stroke or cardiovascular death. During follow-up, 7.4% of women had a 
primary outcome event in contrast to 13.4% of men and 10.0% of South Asians had an 
event compared with 11.5% of non-South Asians. 
 
Is CACS a significant predictor of primary outcome events in the PREDICT cohort? 
Incidence rates and numbers of primary outcome events in each CACS category are 
shown in Table 2. The highest proportions of fatal, stroke and CHD primary endpoints 
were in the category CACS>1000AU (results not shown). In Cox proportional hazards 
modeling, CACS was entered in the model as base 2 log(CACS+1). Logarithmic 
transformation rendered the relationship between CACS and primary outcome event rate 
approximately linear up to a calcification score of 1000 (Figure 2) and markedly 
improved model prediction (likelihood ratio: untransformed 20.2; transformed 37.2). Use 
of base 2 log enabled the effect of a doubling in CACS to be determined. CACS was 
significantly related to endpoint-free survival time (Table 3) and a doubling of CACS 
was associated with a 32% increase in risk of a primary outcome event. With a doubling 
of CACS, there was a 31% increase in risk for the 56 CHD endpoints alone (p<0.001) 
and a 33% increase in risk for the 29 hard endpoints alone (p<0.001). Successive CACS 
categories were highly significantly related to endpoint-free follow-up time (Table 3). 
The proportions of primary endpoints according to follow-up time in each CACS 
category are shown in Figure 3. Only 9% of patients had a CACS score of >1000, but this 
group accounted for 25% of all patients experiencing first endpoints (unadjusted HR 19. 
8 95% CI (4.6, 86.0)).  
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Does CACS predict events independently of other, more readily measurable, risk factors? 
Among the classical risk factors only age (p=0.006), male gender (p=0.01) and increased 
levels of SBP (0.04) were significant univariate predictors of endpoint-free follow-up 
time. Among the other risk factors only serum creatinine (p=0.01) and HOMA-IR 
(p=0.02) were significant predictors. There was little evidence for significant interactions 
between CACS and other risk factors, including age, duration of diabetes and HbA1c 
level. In multivariable analysis, with entry of classical risk factors plus serum creatinine 
and HOMA-IR, CACS remained a highly significant predictor of primary endpoints with 
a doubling in CACS being associated with a 29% increase in risk (Table 3). In 
multivariable analysis with entry of CACS categories, prediction by the category 11-100 
AU was reduced to borderline significance (p=0.07), but the three higher CACS 
categories remained significantly predictive. In the fully-adjusted model, with entry of 
CACS either as a continuous or categorical variable, the only other significant predictor 
was HOMA-IR (p=0.01).  
 
Does CACS add to risk prediction provided by the established Framingham and UKPDS risk 
models? 
Framingham CHD risk was a significant predictor of CHD-free survival time (p=0.002). 
With inclusion of CACS in the model, the significance of Framingham CHD risk was 
markedly reduced (p=0.05) and CACS remained significant (p<0.001). In identifying 
those who would experience a CHD event, inclusion of CACS with Framingham risk 
increased the ROC AUC from 0.63 to 0.73 (p=0.01, Table 4). UKPDS CHD risk was a 
significant predictor of CHD-free survival time (p<0.001). With inclusion of CACS in 
the model, the significance of UKPDS CHD risk was markedly reduced (p=0.02) and 
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CACS remained significant (p<0.001). In identifying those who would experience a CHD 
event, inclusion of CACS with UKPDS CHD risk increased the ROC AUC from 0.67 to 
0.75 (p=0.07, Table 4). UKPDS CVD primary end-point risk was a significant predictor 
of CVD-free survival time (p=0.007). With inclusion of CACS in the model, UKPDS 
CVD risk ceased to be significant (p=0.3) and CACS remained significant (p<0.001). In 
identifying those who would experience a CVD event, inclusion of CACS with UKPDS 
CVD risk increased the ROC AUC from 0.63 to 0.73 (p=0.03, Table 4).
 14
 
DISCUSSION 
 
We have shown that CACS is highly predictive of cardiovascular endpoints in patients 
with T2DM with no history of CVD in a prospective study specifically designed to test 
this possibility. The risk of sustaining an endpoint increased with increasing category of 
CACS. Furthermore CACS had greater predictive value for endpoints than a broad range 
of conventional and novel risk factors, and added to the predictive power of the 
Framingham or UKPDS risk scores. Our study differs from most previously reported in 
that it included only patients with T2DM and without known or suspected CVD, who 
were recruited from routine diabetic clinics. Moreover all measurements were 
systematically made at baseline.  
 
Apart from insulin resistance, no other conventional or novel risk factor (including high 
sensitivity CRP, homocysteine, HBA1c, lipids and lipoproteins and albumin creatinine 
ratio) independently predicted cardiovascular endpoints. In the UKPDS 19, as in 
PREDICT, blood pressure was a strong independent predictor of CVD in patients with 
T2DM. However, in the UKPDS, LDL and HDL cholesterol also emerged as important 
predictors 19. On recruitment, PREDICT participants had already been diagnosed with 
diabetes for a mean of 7 years. They will, therefore have been receiving treatment and 
may also have been at a different stage in diabetes-related atherosclerosis from the 
UKPDS participants. The UKPDS risk equation did, nevertheless, provide for significant 
prediction of both CHD and CVD risk in the PREDICT cohort, as did the Framingham 
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equation for CHD. Inclusion of CACS clearly enhanced Framingham CHD risk 
estimation and also enhanced UKPDS CHD risk estimation at borderline significance. 
Importantly CACS enhanced UKPDS risk estimation for PREDICT CVD primary 
endpoints. 
 
In previously-published, cross-sectional analyses of baseline relationships, we found 
relatively few associations between other risk factors and CACS; only age, waist hip 
ratio, duration of diabetes and male gender were independently related 12, 13. In the 
present analysis, age and male gender predicted primary endpoints, but not independently 
of CACS and neither waist hip ratio nor duration of diabetes were predictive, either in 
univariate or multivariable analysis. Correlates of CACS were therefore relatively weak 
as predictors of cardiovascular endpoints compared with CACS per se. 
 
In non-diabetic subjects, several studies have shown that CACS predicts cardiac events in 
symptomatic and asymptomatic individuals 5, 6, 18. Recently investigators from the Multi-
Ethnic Study of Atherosclerosis (MESA) have reported on the predictive power for 
coronary events of CACS in an ethnically-weighted population sample of 6722 men and 
women 20. They found that a doubling in CACS was associated with a 26% increase in 
risk of CHD. This high risk compares with our finding of a 31% increase in risk in 
patients with T2DM, as did their finding that CACS added significantly to prediction by 
conventional risk factors. There is less information about the predictive value of CACS in 
those with diabetes. CACS predicted all cause mortality in the 8.7 percent of diabetic 
participants in a large observational study (n=10,377) and added to the predictive power 
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of the Framingham score 17.  Moreover for those patients with undetectable coronary 
artery calcification, mortality was similar to that of non-diabetic individuals. However, 
risk factors were not measured systematically at baseline and participants had been 
referred for risk assessment and may, therefore, have not been representative of a more 
general diabetic population. In another study in patients with T2DM, CACS was found to 
be superior to established risk factors in identifying subjects with silent myocardial 
ischaemia, assessed by perfusion scintigraphy 21. First coronary heart disease and stroke 
events were also analysed in the 510 participants, but there were only 2.2 years of follow-
up and 20 events. CACS was, nevertheless, a stronger predictor of events than 
conventional risk factors or scores. 
 
Our study has limitations. Although risk of cardiovascular events increased 
monotonically in successive categories of CACS, confidence intervals overlapped 
between categories, reflecting the relatively small numbers of events in each of the 
categories we analysed. There was an unexpected lack of association between established 
risk factors and the primary outcomes, which could relate to the treatments PREDICT 
participants were taking, particularly the prevalent use (46%) of lipid modifying drugs. 
Whether treating to achieve lower lipid and blood pressure targets in patients with high 
CACS will be of value remains to be established. Also further studies will be needed to 
ascertain whether CACS is equally predictive of cardiovascular events among people of 
Black African origin with T2DM. 
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Our study identified a group with low CACS (≤10 AU), comprising 23 percent of our 
sample, who appear at relatively low risk for cardiovascular events and in whom use of 
statins, for example, may not be necessary. This could be an important consideration in 
the light of a recent meta-analysis of trials of cholesterol-lowering by statins which  
found an inverse relationship between achieved levels of LDL cholesterol and potential 
side effects 22. Conversely, we have identified high risk groups in whom more intensive 
preventive therapy and investigation may be warranted. 
 
The measurement of CACS will become more readily available with the use of multi-
detector computed tomography (MDCT), and levels of calcification that can be reliably 
distinguished by this technique and EBCT (CACS >10 AU) are highly comparable 23. 
Our findings indicate that measurement of coronary artery calcification in patients with 
established T2DM without evidence of CVD is a powerful tool for evaluating future risk 
of cardiovascular events that can enhance risk evaluation in these patients beyond that 
provided by current methods. Whether it becomes a routine procedure will depend on 
consideration of cost benefit relative to measurement of conventional risk factors. 
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Table 1: Group characteristics  
 
For the 589 PREDICT study patients who had coronary artery calcification score (CACS) 
measured, numbers and percentages for categorical variables in each category are given 
and for continuous variables, medians and interquartile ranges. 
 
 
 
 
N (%) 
  
Coronary artery calcification (AU)   
CACS 0-10 138 (23.4) 
CACS 11-100 150 (25.5) 
CACS 101-400 151 (25.6) 
CACS 401-1000 89 (15.1) 
CACS 1001-10000 61 (10.4) 
  
Male 373 (63.3) 
Caucasian 419 (71.1) 
Asian Indian 120 (20.4) 
Non-smoker 261 (44.3) 
Ex-smoker 239 (40.6) 
Current cigarette smoker 89 (15.1) 
Other current smoker 34 (5.8) 
Alcohol (>28 units/wk) 35 (5.9) 
Exercise (regular or aerobic) 466 (79.1) 
Oral hypoglycaemic therapy 475 (80.6) 
Insulin therapy 147 (25.0) 
Statin therapy 225 (38.2) 
Fibrate therapy 49 (8.3) 
BP-lowering therapy 373 (63.3) 
Metabolic syndrome (IDF) 440 (74.7) 
 
 
  
Median (IQR) 
  
Age (yr) 63.1 (56.8, 68.5) 
Duration of diabetes (years) 7 (3, 13) 
BMI (kg/m2) 28.7 (25.5, 32.2) 
Waist circumference (cm) 99 (90.5, 108) 
Waist hip ratio (x100) 96.6 (90, 102.1) 
Systolic BP (mmHg) 131 (121, 142) 
Diastolic BP (mmHg) 78 (72, 84) 
Heart rate (per min) 74 (66, 81) 
HbA1c (%) 7.7 (6.9, 9.2) 
Fasting plasma glucose (mmol/l) 8.9 (7.3, 11.5) 
Urine albumin creatinine ratio 1.2 (0.7, 3.3) 
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Serum creatinine (μmol/l) 98 (90, 109) 
Total cholesterol (mmol/l) 4.7 (4.1, 5.4) 
LDL cholesterol (mmol/l) 2.7 (2.2-3.3) 
HDL cholesterol (mmol/l) 1.1 (0.9, 1.3) 
Triglycerides (mmol/l) 1.5 (1.2, 2.3) 
Triglycerides HDL cholesterol ratio 1.4 (0.9, 2.2) 
Total / HDL cholesterol ratio 4.1 (3.4, 5) 
Fasting plasma insulin (pmol/l) 0.9 (0.4, 2.3) 
HOMA-IR 0.3 (0.2, 1) 
Apolipoprotein AI (mg/dl) 141.9 (125.4, 162.4) 
Apolipoprotein B (mg/dl) 95.9 (81.5, 109.6) 
ApoAI / ApoB ratio 1.5 (1.2, 1.8) 
Fibrinogen (g/l) 3.3 (2.7, 3.9) 
C-reactive protein (mg/dl) 0.3 (0.1, 0.5) 
Homocysteine (µmol/l) 10.3 (8.3, 12.7) 
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Table 2. Primary endpoint and risk factor characteristics by CACS category 
Medians and interquartile ranges are shown, except where indicated. Significant differences across categories were present (p<0.05) 
for all variables except HbA1c, total cholesterol, HDL cholesterol, Triglycerides and HOMA-IR. 
 
Variable 0-10 AU 11-100 AU 101-400 AU 401-1000 AU 1001-10000 AU
Number in CACS category  
(%) 138 (23) 150 (26) 151 (26) 89 (15) 61 (10) 
Primary endpoint event rate, 
incidence per 103 person years (n) 4 (2) 21 (12) 40 (22) 45 (14) 75 (16) 
Male 
n (%) 63 (46) 96 (64) 97 (64) 67 (75) 50 (82) 
Statin therapy 
n (%) 43 (31) 51 (34) 70 (46) 43 (48) 18 (30) 
Age 
(yr) 59 (54, 65) 62 (56, 67) 64 (59, 70) 65 (60, 70) 68 (60, 71) 
Duration of diabetes  
(years) 6 (2, 11) 7 (3, 12) 8 (3, 14) 9 (5, 13) 10 (4, 15)
Waist/Hip ratio  
(x100) 92 (86, 100) 97 (90, 103) 97 (91, 103) 98 (93, 103) 98 (94, 104) 
Systolic BP  
(mmHg) 127 (116, 135) 130 (120, 142) 134 (123, 145) 135 (124, 146) 134 (124, 142) 
HbA1c  
(%) 7.9 (7, 8.9) 7.6 (6.8, 9.2) 7.7 (6.9, 9.3) 7.4 (7, 9.1) 7.8 (6.9, 9.7) 
Urine albumin creatinine ratio 
 0.95 (0.6, 2.1) 1.3 (0.7, 4) 1.3 (0.75, 3.8) 1.3 (0.7, 3.3) 1.3 (0.7, 3.8) 
Total cholesterol  
(mmol/l) 4.9 (4.2, 5.4) 4.7 (4.2, 5.4) 4.7 (4.1, 5.4) 4.6 (4.1, 5.5) 4.6 (4.1, 5.2) 
LDL cholesterol  
(mmol/l) 2.7 (2.2, 3.3) 2.7 (2.3, 3.3) 2.7 (2.2-3.3) 2.7 (2.1, 3.3) 2.6 (2.2, 3.2) 
HDL Cholesterol  
(mmol/l) 1.2 (1, 1.4) 1.1 (0.93, 1.4) 1.1 (0.94, 1.3) 1.1 (0.95, 1.4) 1 (0.91, 1.3) 
Triglycerides  
(mmol/l) 1.5 (1.2, 2.2) 1.5 (1.1, 2.1) 1.5 (1.2, 2.3) 1.7 (1.2, 2.3) 1.6 (1.1, 2.3) 
HOMA-IR 
 0.3 (0.13, 0.86) 0.35 (0.16, 1) 0.34 (0.15, 0.98) 0.47 (0.16, 1) 0.45 (0.17, 1) 
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Table 3: Prediction of first cardiovascular events (n=66) by coronary artery calcium category in the PREDICT cohort  
 
Hazard ratios and 95% confidence intervals (HR, 95% CI, respectively) for Cox proportional hazards model are shown. In the fully-
adjusted model the classical risk factors, age, sex, South Asian ethnicity, cigarette smoking, duration of diabetes, cholesterol, HDL cholesterol, 
systolic BP, diastolic BP, antihypertensive use, lipid-lowering use plus the significant univariate predictors serum creatinine and HOMA-IR 
were entered stepwise. 
 
  Unadjusted model (n=589)* Fully-adjusted model (n=556)* 
Coronary artery calcification (CACS) HR (95% CI) significance HR (95% CI) significance 
     
Continuous     
log2 (CACS+1) 1.320 (1.195, 1.459) <0.001 1.292 (1.156, 1.443) <0.001 
Categorical         
CACS 0-10 1.000 (Reference)   1.000 Reference   
CACS 11-100 5.409 (1.210, 24.169) 0.02 4.001 (0.867, 18.465) 0.07 
CACS 101-400 10.491 (2.467, 44.622) 0.001 7.090 (1.604, 31.330) 0.01 
CACS 401-1000 11.915 (2.707, 52.442) 0.001 8.391 (1.843, 38.209) 0.006 
CACS 1001-10000 19.770 (4.545, 85.998) <0.001 13.793 (3.067, 62.041) 0.008 
 
* Likelihood ratios for the unadjusted and fully-adjusted models with CACS entered as a continuous variable were 37.1 and 44.6, 
respectively, both p<0.001 
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Table 4: Framingham and UKPDS Risk Engine estimates of coronary heart disease risk 
and UKPDS cardiovascular disease risk as predictors of case status without and with 
CACS 
 
Areas under the receiver operator characteristic curves and 95% confidence intervals 
(AUC ROC, 95% CI, respectively) are shown for each risk score as a predictor of 
whether a PREDICT participant would experience a CHD event (n=56) or CVD event 
(n=66). Significances for the differences between AUC ROC without and with inclusion 
of CACS in the model are shown. 
 
 
  Risk score alone Risk score + CACS  
 n AUC ROC (95% CI) AUC ROC (95% CI) p 
Framingham CHD risk 572 0.63 (0.55, 0.71) 0.74 (0.67, 0.80) 0.01 
UKPDS CHD risk 566 0.67 (0.60, 0.75) 0.75 (0.68, 0.81) 0.07 
UKPDS CVD risk* 576 0.63 (0.56, 0.71) 0.73 (0.67, 0.79) 0.03 
 
*  Framingham CVD risk was not analysed because this includes peripheral vascular 
disease (PVD) as an endpoint. This was not a PREDICT endpoint and in a diabetic cohort 
PVD adds substantially to the number of endpoints predicted by the Framingham CVD 
equation.
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Legend to Figure 1 
 
Proportions of patients with an event with increasing time since recruitment into the 
PREDICT study 
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Legend to Figure 2 
 
Primary endpoint event rates in successive categories of coronary artery calcification 
score. Each unit increase in log2 (CACS+1) represents a doubling in CACS. The 
calcification score categories 0-10, 11-100, 101-400, 401-1000 and 1001-10000 include 
log-transformed CACS categories 1-4, 4-7, 7-9, 9-10 and 11 respectively. Dotted lines 
show 95% confidence intervals. 
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Legend to Figure 3 
 
Proportions of patients with an event with increasing time since recruitment into the 
PREDICT study in successive coronary artery calcification score categories (Agatston 
Units).
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